Jan Lehmann
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Jan Lehmann has a total of 141 co-authors. Here are the top co-authors by number of shared publications:
Michael Stöckle
Department of Urology, Saarland University, Homburg, Germany
6 shared publications- Helge Taubert
Department of Urology and Pediatric Urology, Uniklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany
5 shared publications - Arndt Hartmann
Institute of Pathology University Hospital Erlangen, Friedrich‐Alexander‐Universität Erlangen‐Nürnberg (FAU) Erlangen Germany
4 shared publications - Bastian Keck
Department of Urology, University Hospital Erlangen, Erlangen, Germany
4 shared publications - Bernd Wullich
Urologische und Kinderurologische Klinik, Universitätsklinikum Erlangen, Erlangen, Deutschland
4 shared publications Arndt Hartmann
University Erlangen
3 shared publications
Latest Publications
- Open Access
- 24 April 2024
- Published by Springer Nature in Journal of Cancer Survivorship
- Vol. 19 (5) , 1651-1665
Long-term quality of life of testicular cancer survivors differs according to applied adjuvant treatment and tumour type
Purpose: To evaluate the quality of life (QoL) in long-term testicular cancer (TC) survivors. Methods: QoL was assessed in TC survivors treated between March 1976 and December 2004 (n = 625) using the EORTC-QLQ-C30 questionnaire, including a TC module. The assessment was performed at two time points (2006: response rate: n = 201/625 (32.2%), median follow-up (FU): 12.9 years (range 1.1–30.9); 2017: response rate: n = 95/201 (47.3%), median FU: 26.2 years (range: 13.0–41.2)). TC survivors were grouped according to treatment strategy, tumour entity, clinical stage and prognosis group. Linear and multiple linear regression analyses were performed, with age and time of follow-up as possible confounders. Results: Radiation therapy (RT) compared to retroperitoneal lymph node dissection (RPLND) was associated with a higher impairment of physical function (2017: β = − 9.038; t(84) = − 2.03; p = 0.045), role function (2017: β = − 12.764; t(84) = − 2.00; p = 0.048), emotional function (2006: β = − 9.501; t(183) = − 2.09; p = 0.038) and nausea (2006: β = 6.679; t(185) = 2.70; p = 0.008). However, RT was associated with a lower impairment of sexual enjoyment (2017: symptoms: β = 26.831; t(64) = 2.66; p = 0.010; functional: β = 22.983; t(65) = 2.36; p = 0.021). Chemotherapy (CT), compared to RPLND was associated with a higher impairment of role (2017: β = − 16.944; t(84) = − 2.62; p = 0.011) and social function (2017: β = − 19.160; t(79) = − 2.56; p = 0.012), more insomnia (2017: β = 19.595; t(84) = 2.25; p = 0.027) and greater concerns about infertility (2017: β = 19.830; t(80) = 2.30; p = 0.024). In terms of tumour type, nonseminomatous germ cell tumour (NSGCT) compared to seminoma survivors had significantly lower impairment of nausea (2006: β = − 4.659; t(187) = − 2.17; p = 0.031), appetite loss (2006: β = − 7.554; t(188) = − 2.77; p = 0.006) and future perspective (2006: β = − 12.146; t(175) = − 2.08; p = 0.039). On the other hand, surviving NSGCT was associated with higher impairment in terms of sexual problems (2006: β = 16.759; t(145) = 3.51; p < 0.001; 2017: β = 21.207; t(63) = 2.73; p = 0.008) and sexual enjoyment (2017: β = − 24.224; t(66) = − 2.76; p = 0.008). Conclusions: The applied adjuvant treatment and the tumour entity had a significant impact on the long-term QoL of TC survivors, even more than 25 years after the completion of therapy. Both RT and CT had a negative impact compared to survivors treated with RPLND, except for sexual concerns. NSGCT survivors had a lower impairment of QoL compared to seminoma survivors, except in terms of sexual concerns. Implications for Cancer Survivors: Implications for cancer survivors are to raise awareness of aspects of long-term and late effects on QoL in TC survivors; offer supportive care, such as psycho-oncological support or lifestyle modification, if a deterioration in QoL is noticed; and avoid toxic treatment without compromising a cure whenever possible.
- 24 April 2024
- Published by Springer Nature in Journal of Cancer Survivorship
- Vol. 19 (5) , 1651-1665
Open AccessLong-term quality of life of testicular cancer survivors differs according to applied adjuvant treatment and tumour type
Purpose: To evaluate the quality of life (QoL) in long-term testicular cancer (TC) survivors. Methods: QoL was assessed in TC survivors treated between March 1976 and December 2004 (n = 625) using the EORTC-QLQ-C30 questionnaire, including a TC module. The assessment was performed at two time points (2006: response rate: n = 201/625 (32.2%), median follow-up (FU): 12.9 years (range 1.1–30.9); 2017: response rate: n = 95/201 (47.3%), median FU: 26.2 years (range: 13.0–41.2)). TC survivors were grouped according to treatment strategy, tumour entity, clinical stage and prognosis group. Linear and multiple linear regression analyses were performed, with age and time of follow-up as possible confounders. Results: Radiation therapy (RT) compared to retroperitoneal lymph node dissection (RPLND) was associated with a higher impairment of physical function (2017: β = − 9.038; t(84) = − 2.03; p = 0.045), role function (2017: β = − 12.764; t(84) = − 2.00; p = 0.048), emotional function (2006: β = − 9.501; t(183) = − 2.09; p = 0.038) and nausea (2006: β = 6.679; t(185) = 2.70; p = 0.008). However, RT was associated with a lower impairment of sexual enjoyment (2017: symptoms: β = 26.831; t(64) = 2.66; p = 0.010; functional: β = 22.983; t(65) = 2.36; p = 0.021). Chemotherapy (CT), compared to RPLND was associated with a higher impairment of role (2017: β = − 16.944; t(84) = − 2.62; p = 0.011) and social function (2017: β = − 19.160; t(79) = − 2.56; p = 0.012), more insomnia (2017: β = 19.595; t(84) = 2.25; p = 0.027) and greater concerns about infertility (2017: β = 19.830; t(80) = 2.30; p = 0.024). In terms of tumour type, nonseminomatous germ cell tumour (NSGCT) compared to seminoma survivors had significantly lower impairment of nausea (2006: β = − 4.659; t(187) = − 2.17; p = 0.031), appetite loss (2006: β = − 7.554; t(188) = − 2.77; p = 0.006) and future perspective (2006: β = − 12.146; t(175) = − 2.08; p = 0.039). On the other hand, surviving NSGCT was associated with higher impairment in terms of sexual problems (2006: β = 16.759; t(145) = 3.51; p < 0.001; 2017: β = 21.207; t(63) = 2.73; p = 0.008) and sexual enjoyment (2017: β = − 24.224; t(66) = − 2.76; p = 0.008). Conclusions: The applied adjuvant treatment and the tumour entity had a significant impact on the long-term QoL of TC survivors, even more than 25 years after the completion of therapy. Both RT and CT had a negative impact compared to survivors treated with RPLND, except for sexual concerns. NSGCT survivors had a lower impairment of QoL compared to seminoma survivors, except in terms of sexual concerns. Implications for Cancer Survivors: Implications for cancer survivors are to raise awareness of aspects of long-term and late effects on QoL in TC survivors; offer supportive care, such as psycho-oncological support or lifestyle modification, if a deterioration in QoL is noticed; and avoid toxic treatment without compromising a cure whenever possible.
- Open Access
- 1 April 2023
- Published by Taylor & Francis in ClinicoEconomics and Outcomes Research
- Vol. ume 15, 227-237
Healthcare Resource Utilization and Cost Burden of BCG-Treated Non-Muscle Invasive Bladder Cancer Patients in Germany: A Retrospective Claims Analysis
Background: Intermediate and high-risk non-muscle-invasive bladder cancer (NMIBC) is typically managed with transurethral resection of the bladder tumour (TURBT) followed by intravesical Bacillus Calmette–Guérin (BCG) immunotherapy; however, NMIBC patients can become refractory or unresponsive to BCG treatment, and/or progress to muscle-invasive bladder cancer (MIBC). Healthcare resource utilization (HCRU) and costs in these patient populations are high. Methods: A retrospective longitudinal cohort design of adult (≥ 18 years) patients with bladder cancer and BCG treatment (01/01/2012– 31/12/2017) was conducted using data from a representative subset of the German statutory health insurance database. During the follow-up period after last BCG, patients were categorized into subgroups of No further NMIBC treatment, Continuous treatment for NMIBC, or MIBC evidence; HCRU and costs were tabulated for each subgroup and for the entire cohort. Results: A total of 1049 patients met the study inclusion criteria (mean age, 70.9 years; 84.8% male). Across the different subgroups, patients showing MIBC evidence had more than two times higher hospitalization rates compared to the other subgroups. Overall, the entire BCG-treated cohort’s total direct medical cost including hospitalizations, outpatient care and drugs was € 33.9 million and € 9250 per patient-year. Cost for patients with MIBC evidence was much higher, at € 17,983 per patient-year, than patients with No further NMIBC treatment (€ 6617) and patients with Continuous treatment for NMIBC (€ 7786). Across the subgroups, hospitalization was the largest driver of cost and contributed the most to cost for those with MIBC evidence. Conclusion: The overall cost burden of this BCG-treated cohort of 1049 patients is high (€ 38 million whereof 4.1 million are indirect costs) over a mean follow-up of 3.9 years; economic burden is especially substantial for patients who fail BCG treatment and those who progress.
- 1 April 2023
- Published by Taylor & Francis in ClinicoEconomics and Outcomes Research
- Vol. ume 15, 227-237
Open AccessHealthcare Resource Utilization and Cost Burden of BCG-Treated Non-Muscle Invasive Bladder Cancer Patients in Germany: A Retrospective Claims Analysis
Background: Intermediate and high-risk non-muscle-invasive bladder cancer (NMIBC) is typically managed with transurethral resection of the bladder tumour (TURBT) followed by intravesical Bacillus Calmette–Guérin (BCG) immunotherapy; however, NMIBC patients can become refractory or unresponsive to BCG treatment, and/or progress to muscle-invasive bladder cancer (MIBC). Healthcare resource utilization (HCRU) and costs in these patient populations are high. Methods: A retrospective longitudinal cohort design of adult (≥ 18 years) patients with bladder cancer and BCG treatment (01/01/2012– 31/12/2017) was conducted using data from a representative subset of the German statutory health insurance database. During the follow-up period after last BCG, patients were categorized into subgroups of No further NMIBC treatment, Continuous treatment for NMIBC, or MIBC evidence; HCRU and costs were tabulated for each subgroup and for the entire cohort. Results: A total of 1049 patients met the study inclusion criteria (mean age, 70.9 years; 84.8% male). Across the different subgroups, patients showing MIBC evidence had more than two times higher hospitalization rates compared to the other subgroups. Overall, the entire BCG-treated cohort’s total direct medical cost including hospitalizations, outpatient care and drugs was € 33.9 million and € 9250 per patient-year. Cost for patients with MIBC evidence was much higher, at € 17,983 per patient-year, than patients with No further NMIBC treatment (€ 6617) and patients with Continuous treatment for NMIBC (€ 7786). Across the subgroups, hospitalization was the largest driver of cost and contributed the most to cost for those with MIBC evidence. Conclusion: The overall cost burden of this BCG-treated cohort of 1049 patients is high (€ 38 million whereof 4.1 million are indirect costs) over a mean follow-up of 3.9 years; economic burden is especially substantial for patients who fail BCG treatment and those who progress.
- Open Access
- 17 August 2021
- Published by Springer Nature in Der Urologe
- Vol. 61 (2) , 1-9
Einflussfaktoren bei der Wahl der Androgendeprivationstherapie für Patienten mit hormonsensitiven Prostatakarzinom
Zusammenfassung Hintergrund Die Androgendeprivationstherapie (ADT) mit einem GnRH-Agonisten (Gonadotropin-releasing-Hormon) oder -Antagonisten stellt einen zentralen Bestandteil der Behandlung des Prostatakarzinoms (PCa) dar. Über die Faktoren, welche die Wahl der ADT beeinflussen, ist bis jetzt wenig bekannt. Ziele der Arbeit Faktoren, welche die Wahl der ADT bei Patienten mit hormonsensitivem PCa beeinflussen, werden identifiziert. Vom Urologen zur Identifizierung von Begleiterkrankungen genutzte Informationsquellen sowie deren Prävalenzen werden bestimmt. Methoden Die zweiarmige, prospektive, nicht-interventionelle Studie „ProComD“ wurde von Sept. 2014 bis Juni 2019 an 80 Studienzentren in Deutschland durchgeführt. Patienten mit hormonnaivem PCa und Notwendigkeit einer ADT wurden nach erfolgter Therapieentscheidung in die Studie eingeschlossen. Fragen bezüglich Informationsquelle und Therapieentscheidung wurden vom Arzt direkt im elektronischen Datenerfassungssystem (eCRF) beantwortet. Ergebnisse Es wurden Daten von 413 Patienten ausgewertet (Degarelix n = 268; GnRH-Agonisten n = 145). Ausschlaggebend für die Therapieentscheidung waren für beide Behandlungsgruppen u. a. die Faktoren Komorbiditäten (bei 42 % aller Patienten), Compliance (64 %) und Alter (81 %). Die häufigste konsultierte Informationsquelle bzgl. vorhandener Komorbiditäten ist die Anamnese durch den behandelnden Urologen selbst (68,5 % in beiden Gruppen). Bei Patienten mit kardiovaskulären Vorerkrankungen wurde zusätzlich der Arztbrief (45,8 % Degarelix vs. 38,9 % GnRH-Agonisten) oder der Anamnese-Fragebogen (38,9 % Degarelix vs. 20 % GnRH-Agonisten) herangezogen. Schlussfolgerungen Komorbiditäten zählen neben dem Alter und der Compliance zu den wichtigen Faktoren, die die Wahl der ADT beeinflussen.
- 17 August 2021
- Published by Springer Nature in Der Urologe
- Vol. 61 (2) , 1-9
Open AccessEinflussfaktoren bei der Wahl der Androgendeprivationstherapie für Patienten mit hormonsensitiven Prostatakarzinom
Zusammenfassung Hintergrund Die Androgendeprivationstherapie (ADT) mit einem GnRH-Agonisten (Gonadotropin-releasing-Hormon) oder -Antagonisten stellt einen zentralen Bestandteil der Behandlung des Prostatakarzinoms (PCa) dar. Über die Faktoren, welche die Wahl der ADT beeinflussen, ist bis jetzt wenig bekannt. Ziele der Arbeit Faktoren, welche die Wahl der ADT bei Patienten mit hormonsensitivem PCa beeinflussen, werden identifiziert. Vom Urologen zur Identifizierung von Begleiterkrankungen genutzte Informationsquellen sowie deren Prävalenzen werden bestimmt. Methoden Die zweiarmige, prospektive, nicht-interventionelle Studie „ProComD“ wurde von Sept. 2014 bis Juni 2019 an 80 Studienzentren in Deutschland durchgeführt. Patienten mit hormonnaivem PCa und Notwendigkeit einer ADT wurden nach erfolgter Therapieentscheidung in die Studie eingeschlossen. Fragen bezüglich Informationsquelle und Therapieentscheidung wurden vom Arzt direkt im elektronischen Datenerfassungssystem (eCRF) beantwortet. Ergebnisse Es wurden Daten von 413 Patienten ausgewertet (Degarelix n = 268; GnRH-Agonisten n = 145). Ausschlaggebend für die Therapieentscheidung waren für beide Behandlungsgruppen u. a. die Faktoren Komorbiditäten (bei 42 % aller Patienten), Compliance (64 %) und Alter (81 %). Die häufigste konsultierte Informationsquelle bzgl. vorhandener Komorbiditäten ist die Anamnese durch den behandelnden Urologen selbst (68,5 % in beiden Gruppen). Bei Patienten mit kardiovaskulären Vorerkrankungen wurde zusätzlich der Arztbrief (45,8 % Degarelix vs. 38,9 % GnRH-Agonisten) oder der Anamnese-Fragebogen (38,9 % Degarelix vs. 20 % GnRH-Agonisten) herangezogen. Schlussfolgerungen Komorbiditäten zählen neben dem Alter und der Compliance zu den wichtigen Faktoren, die die Wahl der ADT beeinflussen.
- 1 January 2019
- Published by Elsevier in European Journal of Cancer
- Vol. 107, 37-45
SWITCH II: Phase III randomized, sequential, open-label study to evaluate the efficacy and safety of sorafenib-pazopanib versus pazopanib-sorafenib in the treatment of advanced or metastatic renal cell carcinoma (AUO AN 33/11)
- 1 January 2019
- Published by Elsevier in European Journal of Cancer
- Vol. 107, 37-45
SWITCH II: Phase III randomized, sequential, open-label study to evaluate the efficacy and safety of sorafenib-pazopanib versus pazopanib-sorafenib in the treatment of advanced or metastatic renal cell carcinoma (AUO AN 33/11)
- Open Access
- 1 January 2015
- Published by Springer Nature in Molecular Medicine
- Vol. 21 (1) , 371-380
Piwil 2 Expression Is Correlated with Disease-Specific and Progression-Free Survival of Chemotherapy-Treated Bladder Cancer Patients
Piwi-like 2 (Piwil 2) belongs to the family of Argonaute genes/proteins. The expression of Piwil 2 is associated with stem cells. A role in tumorigenesis and/or tumor progression is proposed for different cancers but not yet for bladder cancer (BCa). We investigated the Piwil 2 expression by immunohistochemistry in a cohort of 202 BCa patients treated by cystectomy and adjuvant chemotherapy. The association between Piwil 2 expression and disease-specific (DSS) or progression-free survival (PFS) was calculated using Kaplan Meier analyses and univariate/multivariate Cox's regression hazard models.In a multivariate Cox's regression, Piwil 2 expression, either in the cytoplasm or the nucleus, was significantly associated with DSS and PFS. A weak cytoplasmic staining pattern was associated with poor DSS and tumor progression (RR=2.7; P=0.004 and RR=2.4; P=0.027). Likewise,, absent nuclear Piwil 2 immunoreactivity was associated with poor DSS and tumor progression (RR=2.3; P=0.023 and RR=2.2; P=0.022). BCa patients whose tumors exhibited a combination of weak cytoplasmic and absent nuclear immunoreactivity had a 6-fold increased risk of tumor-related death (P=0.005) compared to patients with strong expression. Considering only patients with high grade G3 tumors, a 7.8-fold risk of tumor-associated death and a 3.6-fold risk of tumor progression were detected independently of the histologic tumor subtype or the chemotherapy regimen. In summary, a combination of weak cytoplasmic and absent nuclear expression of Piwil 2 is significantly associated with an increased risk of DSS and tumor progression. This implicates that Piwil 2 could be a valuable prognostic marker for high-risk BCa patients.
- 1 January 2015
- Published by Springer Nature in Molecular Medicine
- Vol. 21 (1) , 371-380
Open AccessPiwil 2 Expression Is Correlated with Disease-Specific and Progression-Free Survival of Chemotherapy-Treated Bladder Cancer Patients
Piwi-like 2 (Piwil 2) belongs to the family of Argonaute genes/proteins. The expression of Piwil 2 is associated with stem cells. A role in tumorigenesis and/or tumor progression is proposed for different cancers but not yet for bladder cancer (BCa). We investigated the Piwil 2 expression by immunohistochemistry in a cohort of 202 BCa patients treated by cystectomy and adjuvant chemotherapy. The association between Piwil 2 expression and disease-specific (DSS) or progression-free survival (PFS) was calculated using Kaplan Meier analyses and univariate/multivariate Cox's regression hazard models.In a multivariate Cox's regression, Piwil 2 expression, either in the cytoplasm or the nucleus, was significantly associated with DSS and PFS. A weak cytoplasmic staining pattern was associated with poor DSS and tumor progression (RR=2.7; P=0.004 and RR=2.4; P=0.027). Likewise,, absent nuclear Piwil 2 immunoreactivity was associated with poor DSS and tumor progression (RR=2.3; P=0.023 and RR=2.2; P=0.022). BCa patients whose tumors exhibited a combination of weak cytoplasmic and absent nuclear immunoreactivity had a 6-fold increased risk of tumor-related death (P=0.005) compared to patients with strong expression. Considering only patients with high grade G3 tumors, a 7.8-fold risk of tumor-associated death and a 3.6-fold risk of tumor progression were detected independently of the histologic tumor subtype or the chemotherapy regimen. In summary, a combination of weak cytoplasmic and absent nuclear expression of Piwil 2 is significantly associated with an increased risk of DSS and tumor progression. This implicates that Piwil 2 could be a valuable prognostic marker for high-risk BCa patients.
- Open Access
- 20 March 2014
- Published by Springer Nature in BMC Cancer
- Vol. 14 (1) , 214
Loss of MTUS1/ATIP expression is associated with adverse outcome in advanced bladder carcinomas: data from a retrospective study
Seventy percent of all bladder tumours tend to recur and need intensive surveillance, and a subset of tumours progress to muscle-invasive and metastatic disease. However, it is still difficult to find the adequate treatment for every individual patient as it is a very heterogeneous disease and reliable biomarkers are still missing. In our study we searched for new target genes in the critical chromosomal region 8p and investigated the potential tumour suppressor gene candidate MTUS1/ATIP in bladder cancer. MTUS1 was identified to be the most promising deleted target gene at 8p in aCGH analysis with 19 papillary bladder tumours. A correlation with bladder cancer was further validated using immunohistochemistry of 85 papillary and 236 advanced bladder tumours and in functional experiments. Kaplan-Meier analysis and multivariate Cox-regression addressed overall survival (OS) and disease-specific survival (DSS) as a function of MTUS1/ATIP expression. Bivariate correlations investigated associations between MTUS1/ATIP expression, patient characteristics and histopathology. MTUS1 expression was analysed in cell lines and overexpressed in RT112, where impact on viability, proliferation and migration was measured. MTUS1 protein expression was lost in almost 50% of all papillary and advanced bladder cancers. Survival, however, was only influenced in advanced carcinomas, where loss of MTUS1 was associated with adverse OS and DSS. In this cohort, there was also a significant correlation of MTUS1 expression and histological subtype: positive expression was detected in all micropapillary tumours and aberrant nuclear staining was detected in a subset of plasmocytoid urothelial carcinomas. MTUS1 was expressed in all investigated bladder cell lines and overexpression in RT112 led to significantly decreased viability. MTUS1 is a tumour suppressor gene in cultured bladder cancer cells and in advanced bladder tumours. It might represent one new target gene at chromosome 8p and can be used as an independent prognostic factor for advanced bladder cancer patients. The limitation of the study is the retrospective data analysis. Thus, findings should be validated with a prospective advanced bladder tumour cohort.
- 20 March 2014
- Published by Springer Nature in BMC Cancer
- Vol. 14 (1) , 214
Open AccessLoss of MTUS1/ATIP expression is associated with adverse outcome in advanced bladder carcinomas: data from a retrospective study
Seventy percent of all bladder tumours tend to recur and need intensive surveillance, and a subset of tumours progress to muscle-invasive and metastatic disease. However, it is still difficult to find the adequate treatment for every individual patient as it is a very heterogeneous disease and reliable biomarkers are still missing. In our study we searched for new target genes in the critical chromosomal region 8p and investigated the potential tumour suppressor gene candidate MTUS1/ATIP in bladder cancer. MTUS1 was identified to be the most promising deleted target gene at 8p in aCGH analysis with 19 papillary bladder tumours. A correlation with bladder cancer was further validated using immunohistochemistry of 85 papillary and 236 advanced bladder tumours and in functional experiments. Kaplan-Meier analysis and multivariate Cox-regression addressed overall survival (OS) and disease-specific survival (DSS) as a function of MTUS1/ATIP expression. Bivariate correlations investigated associations between MTUS1/ATIP expression, patient characteristics and histopathology. MTUS1 expression was analysed in cell lines and overexpressed in RT112, where impact on viability, proliferation and migration was measured. MTUS1 protein expression was lost in almost 50% of all papillary and advanced bladder cancers. Survival, however, was only influenced in advanced carcinomas, where loss of MTUS1 was associated with adverse OS and DSS. In this cohort, there was also a significant correlation of MTUS1 expression and histological subtype: positive expression was detected in all micropapillary tumours and aberrant nuclear staining was detected in a subset of plasmocytoid urothelial carcinomas. MTUS1 was expressed in all investigated bladder cell lines and overexpression in RT112 led to significantly decreased viability. MTUS1 is a tumour suppressor gene in cultured bladder cancer cells and in advanced bladder tumours. It might represent one new target gene at chromosome 8p and can be used as an independent prognostic factor for advanced bladder cancer patients. The limitation of the study is the retrospective data analysis. Thus, findings should be validated with a prospective advanced bladder tumour cohort.
- 27 June 2013
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 20 (11) , 3669-3674
SNAI1 Protein Expression is an Independent Negative Prognosticator in Muscle-Invasive Bladder Cancer
- 27 June 2013
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 20 (11) , 3669-3674
SNAI1 Protein Expression is an Independent Negative Prognosticator in Muscle-Invasive Bladder Cancer
- Open Access
- 8 February 2013
- Published by Springer Nature in BMC Cancer
- Vol. 13 (1) , 71
Plasmacytoid variant of bladder cancer defines patients with poor prognosis if treated with cystectomy and adjuvant cisplatin-based chemotherapy
Since the definition of different histologic subtypes of urothelial carcinomas by the World Health Organization (WHO) 2004 classification, description of molecular features and clinical behavior of these variants has gained more attention. We reviewed 205 tumor samples of patients with locally advanced bladder cancer mainly treated within the randomized AUO-AB05/95 trial with radical cystectomy and adjuvant cisplatin-based chemotherapy for histologic subtypes. 178 UC, 18 plasmacytoid (PUC) and 9 micropapillary (MPC) carcinomas of the bladder were identified. Kaplan Meier analysis and backward multivariate Cox’s proportional hazards regression analysis were performed to compare overall survival between the three histologic subtypes. Patients suffering from PUC have the worst clinical outcome regarding overall survival compared to conventional UC and MPC of the bladder that in turn seem have to best clinical outcome (27.4 months, 62.6 months, and 64.2 months, respectively; p=0.013 by Kaplan Meier analysis). Backward multivariate Cox´s proportional hazards regression analysis (adjusted to relevant clinicopathological parameters) showed a hazard ratio of 3.2 (p=0.045) for PUC in contrast to patients suffering from MPC. Histopathological diagnosis of rare variants of urothelial carcinoma can identify patients with poor prognosis.
- 8 February 2013
- Published by Springer Nature in BMC Cancer
- Vol. 13 (1) , 71
Open AccessPlasmacytoid variant of bladder cancer defines patients with poor prognosis if treated with cystectomy and adjuvant cisplatin-based chemotherapy
Since the definition of different histologic subtypes of urothelial carcinomas by the World Health Organization (WHO) 2004 classification, description of molecular features and clinical behavior of these variants has gained more attention. We reviewed 205 tumor samples of patients with locally advanced bladder cancer mainly treated within the randomized AUO-AB05/95 trial with radical cystectomy and adjuvant cisplatin-based chemotherapy for histologic subtypes. 178 UC, 18 plasmacytoid (PUC) and 9 micropapillary (MPC) carcinomas of the bladder were identified. Kaplan Meier analysis and backward multivariate Cox’s proportional hazards regression analysis were performed to compare overall survival between the three histologic subtypes. Patients suffering from PUC have the worst clinical outcome regarding overall survival compared to conventional UC and MPC of the bladder that in turn seem have to best clinical outcome (27.4 months, 62.6 months, and 64.2 months, respectively; p=0.013 by Kaplan Meier analysis). Backward multivariate Cox´s proportional hazards regression analysis (adjusted to relevant clinicopathological parameters) showed a hazard ratio of 3.2 (p=0.045) for PUC in contrast to patients suffering from MPC. Histopathological diagnosis of rare variants of urothelial carcinoma can identify patients with poor prognosis.
- 30 October 2012
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 20 (7) , 2440-2445
Nuclear E-cadherin Expression is Associated with the Loss of Membranous E-cadherin, Plasmacytoid Differentiation and Reduced Overall Survival in Urothelial Carcinoma of the Bladder
Loss of E-cadherin represents a hallmark of plasmacytoid differentiation. We analyzed the effect of membranous E-cadherin loss and its nuclear accumulation in patients with locally advanced conventional urothelial carcinoma (UC) who were treated with radical cystectomy and adjuvant chemotherapy.
- 30 October 2012
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 20 (7) , 2440-2445
Nuclear E-cadherin Expression is Associated with the Loss of Membranous E-cadherin, Plasmacytoid Differentiation and Reduced Overall Survival in Urothelial Carcinoma of the Bladder
Loss of E-cadherin represents a hallmark of plasmacytoid differentiation. We analyzed the effect of membranous E-cadherin loss and its nuclear accumulation in patients with locally advanced conventional urothelial carcinoma (UC) who were treated with radical cystectomy and adjuvant chemotherapy.
- Open Access
- 14 April 2011
- Published by Springer Nature in BMC Cancer
- Vol. 11 (1) , 135
Increased expression of transcription factor TFAP2α correlates with chemosensitivity in advanced bladder cancer
The standard treatment for patients with advanced transitional cell carcinoma of the bladder is platin based chemotherapy. Only approximately 50% of the patients respond to chemotherapy. Therefore, molecular predictive markers for identification of chemotherapy sensitive subgroups of patients are highly needed. We selected the transcription factor TFAP2α from a previously identified gene expression signature for chemotherapy response.
- 14 April 2011
- Published by Springer Nature in BMC Cancer
- Vol. 11 (1) , 135
Open AccessIncreased expression of transcription factor TFAP2α correlates with chemosensitivity in advanced bladder cancer
The standard treatment for patients with advanced transitional cell carcinoma of the bladder is platin based chemotherapy. Only approximately 50% of the patients respond to chemotherapy. Therefore, molecular predictive markers for identification of chemotherapy sensitive subgroups of patients are highly needed. We selected the transcription factor TFAP2α from a previously identified gene expression signature for chemotherapy response.